References
- Preisler H. D., Raza A., Larson R., Goldberg J., Tricot C., Browman G., Bennett J. The relationship of in vivo cell cycle characteristics and treatment outcome in acute myelogeneous leukemia to the expression of the FMS and MYC proto‐oncogenes. Leukemia and Lymphoma 1994; 14: 273–278
- Preisler H. D., Raza A., Larson R., LeBeau M., Browman G., Goldberg J., Grunwald H., Vogler R., Verkh I., Singh P., Block A. M., Sandberg A. Protooncogene expression and the clinical characteristics of acute nonlym‐phocytic leukemia: A leukemia intergroup pilot study. Blood 1989; 73: 255–263
- Raza A., Presiler H. D., Li Y. Q., Larson R. A., Goldberg J., Browman G., Bennett J., Grunwald H., Vogler R., Kukla C. Biological characterisitics of newly diagnosed poor prognosis acute myelogenous leukemia. Am. J. Hematol 1993; 42: 359–365
- Raza A., personal communication
- Braun D. P., Harris J. E. Relationship of leukocyte numbers, immunoregulatory cell function and phyto‐hemagglutinin responsiveness in cancer patients. J Natl Cancer Inst 1981; 67: 809–814
- Braun D. P., Ahn M., Chu E., Casey L. C., Harris J. E., Wilbanks B., Siziopikou K. P. Sensitivity of Macrophages from different anatomical sites of cancer patients to arachidonic acid metabolism. Cancer Research 1993; 53: 3362–3368
- Rowe J. M., Nilsson B. I., Simonsson B. Treatment of minimal residual disease in myeloid leukemia; the immunotherapeutic options with emphasis on linomide. Leuk & Lymph. 1993; 11: 321–329
- Beran M., Hansson M., Kiessling R. Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood 1983; 61: 596–599
- Lotzova E. Cytotoxicity and clinical application of activated NK‐cells. Medical Oncolo, and Tumor Pharmacol. 1989; 6: 93–98
- Vidriales M. B., Orfao A., Lopez‐Berges M. C., Bonzalez M., Hernandez J. M., Ciudad J., Lopez A., Moro M. J., Martinez M., San Miguel J. F. Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T‐cell distrubution. Annals of Hematology 1993; 67: 217–222
- Lotzova E., Savary C. A. Interleukin‐2 corrects defective NK activity of patients with leukemia. Comp Immunol Microbiol Infect Dis. 1986; 9: 169–175
- Fujimiya Y., Chang W. C., Bakke A., Horwitx D., Pattengale P. K. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells. Cancer Immunol. Immunother. 1987; 24: 213–220
- Keneko T., Fusauch Y., Kakui Y., Okumura K., Mizoguchi H., Oshimi K. Cytotoxicity of cytokine‐induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leukemia and Lymphoma 1994; 14: 219–229
- Shannon B. T., Finkelstein S., Hester J. P., Fudenberg H. H., Merler E. Altered heterogeneity of monocytes in acute myelomonocytic leukemia. J. Natl. Cancer Inst. 1983; 71: 1157–1163
- Dinarello C. H. Biology of interleukin. FASEB J. 1988; 2: 108–115
- Philip R., Epstein L. B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma‐interferon and interleukin‐1. Nature 1986; 323: 86–89
- Keller R., Keist R., Wechsler A., Leist T. P., van der Meide P. H. Mechanisms of macrophage‐mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int. J. Cancer 1990; 46: 682–686
- Ming W. J., Bersani L., Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J. Immunol. 1987; 138: 1469–1474
- Witsell A. L., Schook L. B. Tumor necrosis factor α is an autocrine growth regulator during macrophage differentiation. Proc. Natl Acad. Sci. USA 1992; 89: 4754–4758
- Fleer A., Roos D., von dem Borne A. E. G. Kr., Engelfriet C. P. Cytotoxicity of human monocytes against sensitized erythrocytes. Mononuclear Phagocytes‐Part II, R. van Furth. Martinus Nijhoff Publishers, Boston 1980; 1761–1774